Biogen Inc.

Total Valuation

Biogen Inc. carries a market capitalization of 24.46B, placing it among publicly traded companies globally. Its enterprise value stands at 28.49B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Biogen Inc. currently has 147.60M shares outstanding.

Valuation Ratios

Biogen Inc. trades at a trailing price-to-earnings ratio of 19.11. The price-to-sales ratio is 2.64, and the price-to-book ratio stands at 1.26.

Enterprise Valuation

On an enterprise value basis, Biogen Inc. trades at an EV/EBITDA multiple of 9.18 and an EV/FCF ratio of 9.20. The EV/Sales ratio of 2.87 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 12.37 provides insight into valuation relative to core operating earnings.

Financial Position

Biogen Inc. maintains a current ratio of 3.06, meaning it holds 3.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 35.18, indicating elevated leverage, while an interest coverage ratio of 11.29 demonstrates strong ability to service its debt obligations.

Financial Efficiency

Biogen Inc. posts a return on equity of 6.80 and a return on invested capital of 7.86.

Taxes

Over the trailing twelve months, Biogen Inc. has paid 251.10M in income taxes, reflecting an effective tax rate of 15.47.

Stock Price Statistics

Biogen Inc.'s stock has gained approximately 41.24467% over the past 52 weeks. The 50-day moving average sits at 158.78, while the 200-day moving average is 146.02.

Income Statement

Over the trailing twelve months, Biogen Inc. generated 9.94B in revenue and converted that into 1.37B in net income, yielding earnings per share of 9.32. EBITDA reached 3.10B, while operating income came in at 2.30B.

Balance Sheet

Biogen Inc. holds 4.28B in cash and equivalents against 6.56B in total debt, resulting in a net debt position of 2.91B. Total book value stands at 20.87B, with working capital of 6.19B providing operational flexibility.

Cash Flow

Biogen Inc. produced 2.59B in operating cash flow over the past twelve months. After subtracting -274.50M in capital expenditures, free cash flow totaled 2.32B - equivalent to 15.78 per share.

Margins

Biogen Inc. operates with a gross margin of 75.49, reflecting its pricing power and cost economics. The operating margin of 23.18 and net profit margin of 13.81 provide insight into operational efficiency.

Dividends & Yields

Scores

Biogen Inc. posts an Altman Z-Score of 5.34, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.